Dupilumab Therapy vs Narrowband UVB Phototherapy

Dupilumab is a targeted injectable medicine, while narrowband UVB uses scheduled ultraviolet light exposure under clinical supervision.

They differ most in how treatment is delivered. Dupilumab is taken at home after suitable instruction, whereas phototherapy requires attendance at a treatment unit. A clinician considers the skin diagnosis, extent of involvement, itch, prior treatment response, other health conditions, and whether regular visits are realistic.

Dupilumab may be considered when inflammatory eczema remains troublesome despite a dependable skin-care routine and appropriate topical treatment, or when the practical burden of frequent light appointments is too high. It can be useful for widespread disease where a systemic treatment is appropriate.

An injection-based option also calls for comfort with the technique, safe storage, and follow-up. New or persistent eye irritation, redness, pain, or visual changes should be reported promptly because they may need assessment.

Narrowband UVB may fit a person who can attend consistently and prefers a non-injectable approach. It can be used for inflammatory conditions affecting larger areas when topical products alone are not enough, and it allows the clinical team to adjust exposure according to the skin response.

The schedule matters: missed sessions can interrupt progress and may require cautious re-escalation. Tell the team about medicines or skin products that can increase sensitivity to light, and follow the unit's instructions about shielding unaffected areas.

Dupilumab can cause injection-site reactions and may be associated with eye symptoms. Phototherapy can cause temporary redness, dryness, itch, or a sunburn-like reaction if the skin receives more exposure than it tolerates. Neither option replaces routine review when symptoms change.

A rapidly spreading rash, facial swelling, trouble breathing, blistering, fever, or painful skin needs urgent medical assessment. These symptoms are not a reason to self-adjust treatment without clinical advice.

Neither option is automatically the next step for every flare. A clinician may first check whether the diagnosis is correct, whether infection or contact allergy is contributing, and whether the topical regimen is being applied in a workable amount and formulation.

Localised disease may be managed differently from widespread disease. If skin is oozing, crusted, unusually painful, or accompanied by feeling unwell, assessment should happen before arranging routine phototherapy or starting a new injectable medicine.

The decision is usually shared. Your clinician weighs disease severity and location against the demands of each option, then reviews your medical history, current medicines, pregnancy plans, skin sensitivity, and capacity for appointments. The aim is a plan you can use safely and consistently.

Bring a brief record of flares, treatments tried, missed work or sleep, and any eye or light-related reactions. This gives the consultation concrete information for choosing, changing, or combining treatments.